Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from AbSci ( (ABSI) ) is now available.
On May 13, 2025, Absci Corporation announced the initiation of its first-in-human study for ABS-101, marking its transition to a clinical-stage biotech company. The company also shared promising preclinical data for ABS-201, indicating potential for a more effective treatment for androgenetic alopecia. Financially, Absci reported a net loss of $26.3 million for Q1 2025, with cash reserves expected to fund operations into the first half of 2027. The company’s strategic focus remains on advancing its internal pipeline and expanding partnerships, with anticipated new collaborations in 2025.
The most recent analyst rating on (ABSI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.
Spark’s Take on ABSI Stock
According to Spark, TipRanks’ AI Analyst, ABSI is a Neutral.
AbSci’s overall stock score reflects substantial financial challenges, with ongoing losses and negative cash flow being major concerns. While the company’s strategic advancements and partnerships offer long-term potential, these are overshadowed by immediate financial difficulties. Technical analysis suggests bearish trends, and valuation metrics indicate that the stock may be overvalued. Despite some positive outlooks from earnings calls, the overall sentiment remains cautious due to current financial instability.
To see Spark’s full report on ABSI stock, click here.
More about AbSci
Absci is a clinical-stage biopharmaceutical company that utilizes generative design to advance drug discovery and create innovative biologics. The company operates its Integrated Drug Creation™ platform, which combines AI models with a synthetic biology data engine to rapidly design therapeutics targeting challenging medical needs. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City and an Innovation Center in Switzerland.
Average Trading Volume: 3,668,461
Technical Sentiment Signal: Sell
Current Market Cap: $373.7M
Find detailed analytics on ABSI stock on TipRanks’ Stock Analysis page.